Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

25.62 -0.39 (-1.50%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 25, 2023

Via Benzinga

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

July 25, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

What 8 Analyst Ratings Have To Say About Stoke Therapeutics ↗

June 26, 2023

Via Benzinga

Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 24, 2023

Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.

Via Benzinga

Scholastic, Matson, Digital World Acquisition And Other Big Stocks Moving Higher On Friday ↗

July 21, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 90 points on Friday. Here are some big stocks recording gains in today’s session. Digital World Acquisition Corp. (NASDAQ: DWAC) climbed 69%...

Via Benzinga

Analyst Expectations for Stoke Therapeutics's Future ↗

June 08, 2023

Via Benzinga

Analyst Ratings for Stoke Therapeutics ↗

June 08, 2023

Via Benzinga

12 Analysts Have This to Say About Stoke Therapeutics ↗

May 23, 2023

Via Benzinga

Where Stoke Therapeutics Stands With Analysts ↗

May 23, 2023

Via Benzinga

Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

July 21, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 23, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 21, 2023

Via Benzinga

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

June 16, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

What 7 Analyst Ratings Have To Say About Stoke Therapeutics ↗

April 26, 2023

Via Benzinga

Adobe And 2 Other Stocks Insiders Are Selling ↗

May 04, 2023

The S&P 500 closed lower on Wednesday after the Fed increased rates by 25 basis points, as widely expected. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 04, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the BofA Securities Health Care Conference

May 03, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

April 25, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

March 15, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know ↗

March 07, 2023

Via Benzinga

6 Analysts Have This to Say About Stoke Therapeutics ↗

March 07, 2023

Via Benzinga

Expert Ratings for Stoke Therapeutics ↗

January 11, 2023

Via Benzinga

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 06, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

February 27, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

February 07, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

January 09, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.